BYU Professor David Thomson is working to understand a chemical pathway in human muscles that may explain the effects of exercise.

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

Q4 2024 Management View CEO Steve Cutler introduced Barry Balfe as the newly appointed COO, highlighting his 20-year tenure at ICON and focus on strengthening strategic partnerships across the ...

This initiative celebrates the dedication and excellence showcased by visionary leaders and their business ventures.

Austin's status as an emerging hub for life sciences is of particular importance now, because the momentum is expected to help blunt the impact of potentially millions annually in cuts to federal ...

In response to the prospect of a tariff war, representatives of Taiwan’s ruling establishment headed to Washington on February 11 to express their willingness to “work with” the Trump administration.

ICON's fourth-quarter 2024 earnings and revenues beat estimates as it manages to navigate a challenging transition period.

Shareholders who purchased shares of ICLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

Reports Q4 revenue $2.041B, consensus $2.04B. CEO, Dr. Steve Cutler commented, “ICON’s (ICLR) results in quarter four were in-line with our ...

DUBLIN (Reuters) - Ireland's foreign direct investment agency is hopeful that the impact of threatened U.S. tariffs on the country's large pharmaceutical sector will be limited by a U.S. desire to ...

Researchers who have been given access to Google's new AI "co-scientist" tool are enthusiastic about its potential, but it ...